Literature DB >> 10674394

Silencing subdomains of v-ErbA interact cooperatively with corepressors: involvement of helices 5/6.

K Busch1, B Martin, A Baniahmad, J A Martial, R Renkawitz, M Muller.   

Abstract

Members of the thyroid hormone receptor (TR) family act on vertebrate development and homeostasis by activating or repressing transcription of specific target genes in a ligand-dependent way. Repression by TR in the absence of ligand is mediated by an active silencing mechanism. The oncogene v-ErbA is a variant form of TR unable to bind hormone and thus acts as a constitutive repressor. Functional studies and mutation analysis revealed that the TR/v-ErbA silencing domain is composed of three silencing subdomains (SSD1-3) which, although nonfunctional individually, synergize such that silencing activity is restored when they are combined in a heteromeric complex. Here we demonstrate, using protein interaction assays in vitro and in vivo, that the inactive v-ErbA point mutant L489R within helix 5/6 in SSD2 fails to interact with the two corepressors N-CoR (nuclear receptor corepressor) or SMRT (silencing mediator of retinoic acid and thyroid hormone receptor). Furthermore, mutants in SSD1 and SSD3 exhibit a reduced corepressor recruitment corresponding to their weak residual silencing activity. In mammalian two-hybrid assays, only the combination of all three silencing subdomains, SSD1-3, leads to a cooperative binding to the corepressors N-CoR or SMRT comparable to that of the full-length v-ErbA repression domain. In conclusion, full silencing activity requires corepressor interaction with all three silencing subdomains, SSD1-3. Among these, SSD2 is a new target for N-CoR and SMRT and is essential for corepressor binding and function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674394     DOI: 10.1210/mend.14.2.0415

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  1 in total

1.  Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans.

Authors:  Bruno Lefebvre; Yacir Benomar; Aurore Guédin; Audrey Langlois; Nathalie Hennuyer; Julie Dumont; Emmanuel Bouchaert; Catherine Dacquet; Luc Pénicaud; Louis Casteilla; Francois Pattou; Alain Ktorza; Bart Staels; Philippe Lefebvre
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.